Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...
Enhanced cystoscopy at the time of cystectomy and in the outpatient surveillance setting increases detection of high-grade NMIBC. The use of enhanced cystoscopy both in the operating room at the time ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
OSLO, Norway, Oct. 15, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback